DMW – Klinischer Fortschritt, Table of Contents Dtsch Med Wochenschr 2013; 138(31/32): 1557-1560DOI: 10.1055/s-0033-1343262 Angiologie | Commentary Angiologie, Pneumologie © Georg Thieme Verlag KG Stuttgart · New York Lungenembolie Update 2013Pulmonary embolism: update 2013 M. Lankeit 1 Centrum für Thrombose und Hämostase (CTH), Universitätsmedizin der Johannes Gutenberg-Universität Mainz , S. V. Konstantinides 1 Centrum für Thrombose und Hämostase (CTH), Universitätsmedizin der Johannes Gutenberg-Universität Mainz › Author Affiliations Recommend Article Abstract Buy Article Schlüsselwörter SchlüsselwörterLungenembolie - Risikostratifizierung - Thrombolyse - direkte orale Antikoagulanzien Keywords Keywordspulmonary embolism - risk stratification - thrombolysis - direct oral anticoagulants Full Text References Literatur 1 Agnelli G, Buller HR, Cohen A et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699-708 2 Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510 3 Becattini C, Agnelli G, Schenone A et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366: 1959-1967 4 Brighton TA, Eikelboom JW, Mann K et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367: 1979-1987 5 Buller HR, Prins MH, Lensin AW et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297 6 Gibson NS, Sohne M, Kruip MJ et al. Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. Thromb Haemost 2008; 99: 229-234 7 Jaff MR, McMurtry MS, Archer SL et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123: 1788-1830 8 Klok FA, Mos IC, Nijkeuter M et al. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med 2008; 168: 2131-2136 9 Konstantinides S, Lankeit M. Pulmonary embolism hotline 2012. Recent and expected trials. Hamostaseologie 2013; 33: 43-50 10 Lankeit M, Jimenez D, Kostrubiec M et al. Predictive value of the high-sensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation 2011; 124: 2716-2724 11 Lankeit M, Konstantinides S. Is it time for home treatment of pulmonary embolism?. Eur Respir J 2012; 40: 742-749 12 Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352 13 Schulman S, Kearon C, Kakkar AK et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709-718 14 Stein PD, Chenevert TL, Fowler SE et al. Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism (PIOPED III). Ann Intern Med 2010; 152: 434-443 15 The PEITHO Steering Committee. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury. Am Heart J 2012; 163: 33-38 16 Torbicki A, Perrier A, Konstantinides SV et al. Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2008; 29: 2276-2315 17 Zondag W, Kooiman J, Klok F et al. Outpatient versus inpatient treatment in patients with pulmonary embolism. Eur Respir J 2012; Oct 25. [Epub ahead of print]
